BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein isolated from human gastric juice. Its sequence, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, is stable across a wide pH range and resists enzymatic degradation. Decades of preclinical work — primarily from Sikiric and colleagues at the University of Zagreb — document a broad regenerative profile spanning tendon, ligament, muscle, gut epithelium, bone, and neural tissue.
VEGF-Driven Angiogenesis
One of BPC-157's most studied mechanisms is upregulation of vascular endothelial growth factor (VEGF) and its primary receptor, VEGFR2. Angiogenesis is rate-limiting for tissue repair. Without adequate blood supply, fibroblast proliferation and collagen deposition stall. BPC-157 accelerates this bottleneck by promoting VEGFR2 expression and downstream signaling, resulting in faster vascularization of wound beds and reattachment zones in tendon and ligament models (Sikiric et al., 2018, Current Pharmaceutical Design).
FAK-Paxillin Pathway and Cell Migration
BPC-157 activates the focal adhesion kinase (FAK)–paxillin signaling axis, central to cytoskeletal reorganization and directed cell movement. By phosphorylating FAK and paxillin, BPC-157 promotes fibroblast and endothelial cell migration along extracellular matrix gradients, translating in vivo to faster wound closure and reduced scar formation.
GH Receptor Upregulation
BPC-157 appears to sensitize tissue to growth hormone signaling by upregulating GH receptor expression locally, amplifying downstream IGF-1 production and anabolic remodeling at the injury site. This may explain why its effects appear organ-local rather than systemic.
Gut and Mucosal Protection
In animal models of inflammatory bowel disease, NSAID-induced ulceration, and fistula formation, BPC-157 consistently accelerated mucosal healing, reduced inflammatory cytokine expression, and preserved epithelial barrier integrity. It modulates both dopaminergic and serotonergic signaling in the gut-brain axis, contributing to its gastroprotective effects.
Tendon and Ligament Models
Transected Achilles tendon models in rats consistently show faster functional recovery, higher biomechanical strength at the repair site, and superior collagen fiber organization in BPC-157-treated animals. Similar outcomes appear in medial collateral ligament transection and rotator cuff injury models.
Research Status
All published BPC-157 research to date is preclinical. No peer-reviewed human clinical trials have been completed. It is sold exclusively as a research compound for laboratory use only.
Related research compound:
BPC-157 — View Product Page →References
- Sikiric P, et al. (2018). Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design, 24(18), 1994–2003.
- Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol, 110(3), 774–780.
- Gwyer D, et al. (2019). Gastric pentadecapeptide BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res, 377(2), 153–159.